Skip to content

Alexandra Babakanian

2 papers in the library · 152 citations · publishing 2023-2024

Papers

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

Nature Medicine July 24, 2023 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 150 citations

A single 25-mg dose of synthetic psilocybin combined with psychological support was safe, tolerable, and acceptable for 10 adult women with anorexia nervosa or partial remission. No clinically significant changes occurred in electrocardiogram, vital signs, or suicidality. Two participants developed asymptomatic hypoglycemia that resolved within 24 hours. All adverse events were mild and transient. The findings suggest psilocybin therapy may be a promising treatment for female anorexia nervosa, a condition with no FDA-approved medications and high physiological risks.

Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study

FOCUS The Journal of Lifelong Learning in Psychiatry July 1, 2024 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 2 citations

A single 25-mg dose of synthetic psilocybin, given with psychological support, was safe and tolerable for 10 adult women with anorexia nervosa. No clinically significant changes occurred in heart health, vital signs, or suicidality. Two participants had temporary low blood sugar that resolved within a day. All side effects were mild and short-lived. Participants' reports indicated the treatment was acceptable. These results suggest psilocybin therapy may be a safe approach for female anorexia, a condition with no approved medications and high medical risk.